KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Current Leases (2016 - 2025)

Rigel Pharmaceuticals has reported Current Leases over the past 14 years, most recently at $614000.0 for Q4 2025.

  • For Q4 2025, Current Leases rose 115.44% year-over-year to $614000.0; the TTM value through Dec 2025 reached $614000.0, up 115.44%, while the annual FY2025 figure was $614000.0, 115.44% up from the prior year.
  • Current Leases for Q4 2025 was $614000.0 at Rigel Pharmaceuticals, up from $594000.0 in the prior quarter.
  • Over five years, Current Leases peaked at $9.9 million in Q4 2021 and troughed at $285000.0 in Q4 2024.
  • A 5-year average of $3.1 million and a median of $682500.0 in 2023 define the central range for Current Leases.
  • Biggest five-year swings in Current Leases: plummeted 94.59% in 2023 and later soared 115.44% in 2025.
  • Year by year, Current Leases stood at $9.9 million in 2021, then tumbled by 88.55% to $1.1 million in 2022, then plummeted by 38.92% to $692000.0 in 2023, then crashed by 58.82% to $285000.0 in 2024, then soared by 115.44% to $614000.0 in 2025.
  • Business Quant data shows Current Leases for RIGL at $614000.0 in Q4 2025, $594000.0 in Q3 2025, and $517000.0 in Q2 2025.